Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:53 am
| PEG Ratio | 5.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Healthcare Ltd operates in the Hospitals and Medical Services industry, providing a comprehensive range of healthcare services. As of the latest reporting, the company’s stock price stood at ₹912, with a market capitalization of ₹68,867 Cr. Fortis reported a steady growth in revenue, with sales recorded at ₹6,298 Cr for FY 2023, which rose to ₹6,893 Cr in FY 2024 and is projected to reach ₹7,783 Cr by FY 2025. Quarterly sales data shows an upward trajectory from ₹1,607 Cr in September 2022 to ₹1,770 Cr by September 2023, indicating a robust demand for healthcare services. The company has consistently improved its operational performance, reflected in its operating profit margin (OPM) which recorded 20% in FY 2025, up from 19% in FY 2024. The growing revenue stream is supported by an increasing number of patients and expanded service offerings, positioning Fortis as a key player in India’s healthcare sector.
Profitability and Efficiency Metrics
Fortis Healthcare’s profitability metrics demonstrate a favorable trend, with net profit recorded at ₹1,038 Cr for FY 2025, up from ₹633 Cr in FY 2023. The net profit margin improved to 10.25% in FY 2025 from 9.70% in FY 2023, indicating effective cost management and revenue enhancement strategies. The company’s return on equity (ROE) stood at 10.1%, while return on capital employed (ROCE) improved to 12% in FY 2025. The cash conversion cycle (CCC) was reported at -101 days, showcasing excellent efficiency in managing receivables and payables. Fortis’s interest coverage ratio (ICR) also stood strong at 8.97x, reflecting its ability to cover interest obligations comfortably. However, the high price-to-earnings (P/E) ratio of 68.4 suggests that the stock may be overvalued compared to typical sector ranges, which could pose a risk to investors if earnings growth does not keep pace with expectations.
Balance Sheet Strength and Financial Ratios
Fortis Healthcare’s balance sheet exhibits strength, with total assets reported at ₹13,377 Cr and total liabilities at ₹13,377 Cr, indicating a well-managed financial structure. The company holds reserves of ₹8,674 Cr, enhancing its financial stability. Borrowings have increased to ₹3,195 Cr as of September 2025, which raises concerns regarding leverage, but the long-term debt-to-equity ratio remains low at 0.23x, suggesting manageable debt levels. The book value per share stood at ₹118.11, reflecting solid equity backing for shareholders. Additionally, the current ratio is reported at 0.91x, indicating that the company is close to meeting its short-term obligations, although it remains below the ideal benchmark of 1. The enterprise value (EV) to net operating revenue ratio of 7.03x is relatively high, which may indicate that the market has high expectations for future growth.
Shareholding Pattern and Investor Confidence
Fortis Healthcare’s shareholding pattern reveals a diverse mix of ownership, with promoters holding 31.17% and foreign institutional investors (FIIs) at 27.90%. Domestic institutional investors (DIIs) account for 29.14% of the shares, while the public holds 11.79%. The total number of shareholders has increased to 2,20,766, reflecting growing investor confidence in the company. The consistent shareholding by promoters and institutional investors suggests a stable governance structure that may reassure potential investors. However, the declining percentage of public shareholders from 17.44% in December 2022 to 11.79% in September 2025 raises questions about retail investor sentiment. The active participation of institutional investors indicates confidence in Fortis’s long-term growth prospects, which could mitigate risks associated with market volatility.
Outlook, Risks, and Final Insight
Fortis Healthcare’s outlook appears positive, driven by its expanding service offerings and improving financial metrics. However, the company faces risks, including a high P/E ratio that may limit future price appreciation if earnings growth does not meet investor expectations. Additionally, increasing borrowings could pressure financial flexibility, especially in a rising interest rate environment. The healthcare sector is also subject to regulatory changes that may impact operational costs and profitability. Nevertheless, the company’s strong operational efficiency, as indicated by its CCC and OPM, positions it well to navigate these challenges. Should Fortis successfully leverage its established market presence and adapt to evolving healthcare demands, it can enhance shareholder value and sustain growth in the competitive landscape of Indian healthcare services.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.31 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.5 | 20.5/7.08 | 121 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 108 Cr. | 57.7 | 98.7/55.2 | 23.9 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.60 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,030.64 Cr | 690.98 | 90.24 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,607 | 1,560 | 1,643 | 1,657 | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 |
| Expenses | 1,304 | 1,283 | 1,372 | 1,386 | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 | 1,775 |
| Operating Profit | 303 | 276 | 271 | 272 | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 |
| OPM % | 19% | 18% | 16% | 16% | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% | 24% |
| Other Income | 75 | 26 | 26 | 10 | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 | 50 |
| Interest | 33 | 33 | 32 | 31 | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 | 75 |
| Depreciation | 77 | 83 | 82 | 79 | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 | 106 |
| Profit before tax | 268 | 186 | 183 | 171 | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 | 425 |
| Tax % | 19% | 24% | 25% | 27% | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% | 23% |
| Net Profit | 218 | 142 | 138 | 124 | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 |
| EPS in Rs | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 |
Last Updated: January 12, 2026, 9:16 am
Below is a detailed analysis of the quarterly data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,167.00 Cr. (Jun 2025) to 2,331.00 Cr., marking an increase of 164.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,775.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,676.00 Cr. (Jun 2025) to 1,775.00 Cr., marking an increase of 99.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 556.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Jun 2025) to 556.00 Cr., marking an increase of 65.00 Cr..
- For OPM %, as of Sep 2025, the value is 24.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 24.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 19.00 Cr..
- For Interest, as of Sep 2025, the value is 75.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 70.00 Cr. (Jun 2025) to 75.00 Cr., marking an increase of 5.00 Cr..
- For Depreciation, as of Sep 2025, the value is 106.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Jun 2025) to 106.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 425.00 Cr.. The value appears strong and on an upward trend. It has increased from 351.00 Cr. (Jun 2025) to 425.00 Cr., marking an increase of 74.00 Cr..
- For Tax %, as of Sep 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Jun 2025) to 23.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 329.00 Cr.. The value appears strong and on an upward trend. It has increased from 267.00 Cr. (Jun 2025) to 329.00 Cr., marking an increase of 62.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.26. The value appears strong and on an upward trend. It has increased from 3.45 (Jun 2025) to 4.26, marking an increase of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,492 | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 8,434 |
| Expenses | 3,430 | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 6,576 |
| Operating Profit | 62 | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 1,858 |
| OPM % | 2% | 3% | 2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 22% |
| Other Income | 152 | 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 98 |
| Interest | 250 | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 257 |
| Depreciation | 183 | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 407 |
| Profit before tax | -219 | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,292 |
| Tax % | 5% | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | |
| Net Profit | -218 | -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,038 |
| EPS in Rs | -4.73 | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.43 |
| Dividend Payout % | -0% | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 40.37% | 132.31% | 1040.48% | -294.99% | 76.02% | 140.62% | -161.54% | 1510.71% | -19.87% | 1.90% | 25.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 91.94% | 908.17% | -1335.47% | 371.01% | 64.61% | -302.16% | 1672.25% | -1530.59% | 21.77% | 23.53% |
Fortis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 70% |
| 3 Years: | 31% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 48% |
| 3 Years: | 49% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 4:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,820 | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 8,674 |
| Borrowings | 2,550 | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,195 |
| Other Liabilities | 1,018 | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,389 |
| Total Liabilities | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
| Fixed Assets | 4,147 | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 11,703 |
| CWIP | 147 | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 306 |
| Investments | 1,817 | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 220 |
| Other Assets | 1,739 | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,784 |
| Total Assets | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
Below is a detailed analysis of the balance sheet data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 755.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 755.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,674.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,162.00 Cr. (Mar 2025) to 8,674.00 Cr., marking an increase of 512.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,195.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,475.00 Cr. (Mar 2025) to 3,195.00 Cr., marking an increase of 720.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,985.00 Cr. (Mar 2025) to 2,389.00 Cr., marking an increase of 404.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,013.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,703.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,424.00 Cr. (Mar 2025) to 11,703.00 Cr., marking an increase of 1,279.00 Cr..
- For CWIP, as of Sep 2025, the value is 306.00 Cr.. The value appears to be declining and may need further review. It has decreased from 407.00 Cr. (Mar 2025) to 306.00 Cr., marking a decrease of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,784.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,378.00 Cr. (Mar 2025) to 2,784.00 Cr., marking an increase of 406.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
Notably, the Reserves (8,674.00 Cr.) exceed the Borrowings (3,195.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 60.00 | 108.00 | 91.00 | 352.00 | 273.00 | 229.00 | 609.00 | 403.00 | 0.00 | -925.00 | 0.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 |
| Inventory Days | 26 | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 |
| Days Payable | 200 | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 |
| Cash Conversion Cycle | -128 | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 |
| Working Capital Days | -19 | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 |
| ROCE % | 0% | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 27,834,044 | 2.78 | 2558.23 | N/A | N/A | N/A |
| Kotak Midcap Fund | 24,724,343 | 3.76 | 2272.41 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 13,542,021 | 2.96 | 1244.65 | N/A | N/A | N/A |
| Axis Midcap Fund | 12,427,065 | 3.55 | 1142.17 | 12,674,257 | 2025-12-15 02:41:06 | -1.95% |
| HDFC Small Cap Fund | 9,440,132 | 2.28 | 867.64 | 9,973,132 | 2025-12-15 02:41:06 | -5.34% |
| DSP Mid Cap Fund | 5,152,245 | 2.39 | 473.54 | 5,166,727 | 2025-12-15 02:41:06 | -0.28% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 4,912,331 | 2.88 | 451.49 | 8,360,144 | 2025-12-07 02:17:25 | -41.24% |
| HDFC Large and Mid Cap Fund | 4,733,349 | 1.51 | 435.04 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 4,200,000 | 1.29 | 386.02 | N/A | N/A | N/A |
| Sundaram Mid Cap Fund | 3,592,166 | 2.47 | 330.16 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Diluted EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Cash EPS (Rs.) | 15.68 | 12.96 | 12.28 | 14.13 | 2.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Revenue From Operations / Share (Rs.) | 103.09 | 91.30 | 83.42 | 75.73 | 53.38 |
| PBDIT / Share (Rs.) | 21.92 | 17.30 | 15.40 | 14.52 | 5.97 |
| PBIT / Share (Rs.) | 16.81 | 12.76 | 11.22 | 10.54 | 2.12 |
| PBT / Share (Rs.) | 13.19 | 11.24 | 10.49 | 12.76 | -0.05 |
| Net Profit / Share (Rs.) | 10.57 | 8.42 | 8.10 | 10.14 | -1.37 |
| NP After MI And SOA / Share (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| PBDIT Margin (%) | 21.26 | 18.94 | 18.46 | 19.17 | 11.19 |
| PBIT Margin (%) | 16.30 | 13.97 | 13.45 | 13.91 | 3.98 |
| PBT Margin (%) | 12.79 | 12.30 | 12.57 | 16.85 | -0.10 |
| Net Profit Margin (%) | 10.25 | 9.22 | 9.70 | 13.39 | -2.57 |
| NP After MI And SOA Margin (%) | 9.94 | 8.68 | 9.34 | 9.70 | -2.72 |
| Return on Networth / Equity (%) | 8.68 | 7.81 | 8.12 | 8.98 | -1.79 |
| Return on Capital Employeed (%) | 10.50 | 9.52 | 7.69 | 7.49 | 1.61 |
| Return On Assets (%) | 5.65 | 4.50 | 4.73 | 4.67 | -0.98 |
| Long Term Debt / Equity (X) | 0.23 | 0.09 | 0.07 | 0.12 | 0.15 |
| Total Debt / Equity (X) | 0.24 | 0.11 | 0.09 | 0.15 | 0.18 |
| Asset Turnover Ratio (%) | 0.57 | 0.53 | 0.09 | 0.07 | 0.05 |
| Current Ratio (X) | 0.91 | 0.44 | 0.98 | 0.89 | 0.84 |
| Quick Ratio (X) | 0.84 | 0.41 | 0.90 | 0.79 | 0.77 |
| Inventory Turnover Ratio (X) | 69.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.99 | 12.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.67 | 8.01 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 90.01 | 87.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.33 | 91.99 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 8.97 | 9.97 | 9.01 | 7.47 | 2.72 |
| Interest Coverage Ratio (Post Tax) (X) | 5.81 | 5.73 | 5.16 | 4.07 | 0.36 |
| Enterprise Value (Cr.) | 54674.02 | 32853.83 | 20823.69 | 23306.97 | 16352.45 |
| EV / Net Operating Revenue (X) | 7.03 | 4.77 | 3.31 | 4.08 | 4.06 |
| EV / EBITDA (X) | 33.04 | 25.16 | 17.90 | 21.26 | 36.26 |
| MarketCap / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| Retention Ratios (%) | 90.00 | 87.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 5.91 | 4.14 | 2.71 | 3.55 | 2.45 |
| Price / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
After reviewing the key financial ratios for Fortis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.68. This value is within the healthy range. It has increased from 12.96 (Mar 24) to 15.68, marking an increase of 2.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.09. It has increased from 91.30 (Mar 24) to 103.09, marking an increase of 11.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 21.92. This value is within the healthy range. It has increased from 17.30 (Mar 24) to 21.92, marking an increase of 4.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 12.76 (Mar 24) to 16.81, marking an increase of 4.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.19. This value is within the healthy range. It has increased from 11.24 (Mar 24) to 13.19, marking an increase of 1.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.57. This value is within the healthy range. It has increased from 8.42 (Mar 24) to 10.57, marking an increase of 2.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For PBDIT Margin (%), as of Mar 25, the value is 21.26. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 21.26, marking an increase of 2.32.
- For PBIT Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 13.97 (Mar 24) to 16.30, marking an increase of 2.33.
- For PBT Margin (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 12.79, marking an increase of 0.49.
- For Net Profit Margin (%), as of Mar 25, the value is 10.25. This value exceeds the healthy maximum of 10. It has increased from 9.22 (Mar 24) to 10.25, marking an increase of 1.03.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.94. This value is within the healthy range. It has increased from 8.68 (Mar 24) to 9.94, marking an increase of 1.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 15. It has increased from 7.81 (Mar 24) to 8.68, marking an increase of 0.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 9.52 (Mar 24) to 10.50, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 5.65, marking an increase of 1.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.23, marking an increase of 0.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.24, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has increased from 0.53 (Mar 24) to 0.57, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1.5. It has increased from 0.44 (Mar 24) to 0.91, marking an increase of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.84, marking an increase of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 69.89. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 69.89, marking an increase of 69.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 20. It has decreased from 12.60 (Mar 24) to 9.99, marking a decrease of 2.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 20. It has decreased from 8.01 (Mar 24) to 6.67, marking a decrease of 1.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.01. This value exceeds the healthy maximum of 70. It has increased from 87.40 (Mar 24) to 90.01, marking an increase of 2.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.33. This value exceeds the healthy maximum of 70. It has increased from 91.99 (Mar 24) to 93.33, marking an increase of 1.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.97. This value is within the healthy range. It has decreased from 9.97 (Mar 24) to 8.97, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.81. This value is within the healthy range. It has increased from 5.73 (Mar 24) to 5.81, marking an increase of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 54,674.02. It has increased from 32,853.83 (Mar 24) to 54,674.02, marking an increase of 21,820.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.03. This value exceeds the healthy maximum of 3. It has increased from 4.77 (Mar 24) to 7.03, marking an increase of 2.26.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 25.16 (Mar 24) to 33.04, marking an increase of 7.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 25, the value is 90.00. This value exceeds the healthy maximum of 70. It has increased from 87.39 (Mar 24) to 90.00, marking an increase of 2.61.
- For Price / BV (X), as of Mar 25, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.91, marking an increase of 1.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Healthcare Ltd:
- Net Profit Margin: 10.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.68% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 67.2 (Industry average Stock P/E: 90.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Phase - VIII, Mohali Punjab 160062 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ashutosh Raghuvanshi | Managing Director & CEO |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Mr. Indrajit Banerjee | Independent Director |
| Ms. Shailaja Chandra | Independent Director |
| Mr. Tomo Nagahiro | Non Executive Director |
| Mr. Dilip Kadambi | Non Executive Director |
| Mr. Lim Tsin Lin | Non Executive Director |
| Mr. Mehmet Ali Aydinlar | Non Executive Director |
| Dr. Prem Kumar Nair | Non Executive Director |
| Mr. Ashok Pandit | Non Executive Director |
| Mr. Leo Puri | Chairman & Ind.Director |
FAQ
What is the intrinsic value of Fortis Healthcare Ltd?
Fortis Healthcare Ltd's intrinsic value (as of 18 January 2026) is ₹766.53 which is 14.45% lower the current market price of ₹896.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹67,678 Cr. market cap, FY2025-2026 high/low of ₹1,105/521, reserves of ₹8,674 Cr, and liabilities of ₹15,013 Cr.
What is the Market Cap of Fortis Healthcare Ltd?
The Market Cap of Fortis Healthcare Ltd is 67,678 Cr..
What is the current Stock Price of Fortis Healthcare Ltd as on 18 January 2026?
The current stock price of Fortis Healthcare Ltd as on 18 January 2026 is ₹896.
What is the High / Low of Fortis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Healthcare Ltd stocks is ₹1,105/521.
What is the Stock P/E of Fortis Healthcare Ltd?
The Stock P/E of Fortis Healthcare Ltd is 67.2.
What is the Book Value of Fortis Healthcare Ltd?
The Book Value of Fortis Healthcare Ltd is 125.
What is the Dividend Yield of Fortis Healthcare Ltd?
The Dividend Yield of Fortis Healthcare Ltd is 0.11 %.
What is the ROCE of Fortis Healthcare Ltd?
The ROCE of Fortis Healthcare Ltd is 12.0 %.
What is the ROE of Fortis Healthcare Ltd?
The ROE of Fortis Healthcare Ltd is 10.1 %.
What is the Face Value of Fortis Healthcare Ltd?
The Face Value of Fortis Healthcare Ltd is 10.0.